A multi-million dollar investment in a US-based project aims to improve consumers’ and clinicians’ critical treatment decisions about drugs and other therapeutic interventions. - News - PharmaTimes
by Mark Greener
https://www.pharmatimes.com/news/multi-million_dollar_boost_for_research_to_improve_drug_use_991142Improving biopharmaceutical companies' technology infrastructure could save the industry hundreds of millions of dollars a year, according to a new study sponsored by the National Institute of Standards and Technology (NIST), a non-regulatory agency
by Mark Greener
https://www.pharmatimes.com/news/improving_biopharmas_tech_infrastructure_could_save_millions_991138MedImmune is feeling on the up after announcing positive results from the second year of treatment with motavizumab (MEDI-524) - a new monoclonal antibody specifically designed to treat respiratory syncytial virus - at the Infectious Diseases
by Mark Greener
https://www.pharmatimes.com/news/medimmune_unveils_positive_motavizumab_results_in_rsv_991056Topamax (topiramate) appears to be an effective and well tolerated treatment for alcohol abuse, according to a study in the Journal of the American Medical Association, potentially extending the franchise of J&J’s blockbuster beyond migraine
by Mark Greener
https://www.pharmatimes.com/news/j_and_js_epilepsy_drug_topamax_tackles_alcohol_abuse_991089The Clinical Trials Directive should be reviewed to improve the harmonisation, transparency and consistency of trial approval and conduct across the European Union, the UK's BioIndustry Association (BIA) argued at a recent joint meeting of the
by Mark Greener
https://www.pharmatimes.com/news/bia_calls_for_revision_of_eu_clinical_trials_directive_991052Most patients do not value the patient information leaflets (PILs) inserted in medicine packs, according to a NHS R&D Health Technology Assessment report published this week. The report is likely to prove influential: the authors presented their
by Mark Greener
https://www.pharmatimes.com/news/patients_do_not_value_pils_hta_report_989457“Ethics is about telling the truth and it is central to scientific integrity,” comments a new report from the European Commission. Ethics for Researchers aims primarily to facilitate “research excellence” in R&D projects supported by the
by Mark Greener
https://www.pharmatimes.com/news/eu_puts_ethics_at_the_heart_of_r_and_d_991063The US market for implantable medical devices will increase by 9.3% a year to reach $43.6 billion in 2011 and $67.3 billion by 2016, market researchers the Freedonia Group suggest in a new report. - News - PharmaTimes
by Mark Greener
https://www.pharmatimes.com/news/new_generation_stents_help_drive_us_implantable_device_market_991165Industry-sponsored studies of breast cancer therapies are more likely to report positive results than those funded in other ways, researchers from the University of North Carolina at Chapel Hill and the Dana Farber Cancer Institute report in a paper
by Mark Greener
https://www.pharmatimes.com/news/does_pharma_bias_breast_cancer_studies_989458Patients need to take at least two-thirds of their osteoporosis medications over two years to reduce their fracture risk, according to research presented at the American College of Rheumatology's Annual Scientific Meeting in Boston, US this week. -
by Mark Greener
https://www.pharmatimes.com/news/osteoporosis_adherence_needs_to_top_two-thirds_to_cut_fracture_risk_991306
